Shares of Puma Biotechnology Inc (NASDAQ:PBYI) have earned a consensus recommendation of “Buy” from the eleven brokerages that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $130.67.
Several analysts have recently commented on the company. Royal Bank of Canada decreased their target price on Puma Biotechnology from $108.00 to $92.00 and set a “sector perform” rating on the stock in a report on Friday, November 10th. They noted that the move was a valuation call. Credit Suisse Group restated an “outperform” rating and set a $136.00 target price on shares of Puma Biotechnology in a report on Wednesday, September 27th. BidaskClub upgraded Puma Biotechnology from a “hold” rating to a “buy” rating in a report on Friday, September 8th. Barclays assumed coverage on Puma Biotechnology in a report on Wednesday, September 6th. They set an “overweight” rating and a $103.00 target price on the stock. Finally, J P Morgan Chase & Co restated a “buy” rating and set a $131.00 target price on shares of Puma Biotechnology in a report on Wednesday, October 4th.
In related news, insider Charles R. Eyler sold 1,322 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $105.46, for a total value of $139,418.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Richard Paul Bryce sold 15,000 shares of the firm’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $120.00, for a total value of $1,800,000.00. Following the completion of the transaction, the senior vice president now owns 42,239 shares in the company, valued at approximately $5,068,680. The disclosure for this sale can be found here. 21.10% of the stock is owned by company insiders.
Shares of Puma Biotechnology (PBYI) traded down $1.50 during mid-day trading on Monday, hitting $98.20. The stock had a trading volume of 1,332,000 shares, compared to its average volume of 1,083,845. Puma Biotechnology has a 12 month low of $28.35 and a 12 month high of $136.90.
Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) EPS for the quarter, topping the consensus estimate of ($2.50) by $0.43. The business had revenue of $6.10 million for the quarter, compared to the consensus estimate of $3.78 million. During the same quarter in the previous year, the company posted ($1.11) EPS. research analysts expect that Puma Biotechnology will post -8.19 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/12/18/puma-biotechnology-inc-pbyi-receives-consensus-recommendation-of-buy-from-analysts.html.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.